Safroneeva Ekaterina, Saner Catherine, Rossel Jean-Benoît, Golay Delphine, Pittet Valérie, Godat Sébastien, Diem Stefan, Aepli Patrick, Sawatzki Mikael, Borovicka Jan, Burgmann Konstantin, Juillerat Pascal, Netzer Peter, Sendensky Alexander, Hruz Petr, Girardin Marc, Biedermann Luc, Greuter Thomas, Vavricka Stephan, Michetti Pierre, Mueller Christoph, Straumann Alex, Schoepfer Alain M
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Institute of Social and Preventive Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
Inflamm Intest Dis. 2018 Mar;2(3):163-170. doi: 10.1159/000486131. Epub 2018 Jan 31.
The prospective, observational Swiss Eosinophilic Esophagitis Cohort Study (SEECS) was set up in 2015 with the following goals in mind: (1) to provide up-to-date epidemiologic data; (2) to assess the appropriateness of care; (3) to evaluate the psychosocial impact; and (4) to foster translational research projects. Data capture relies on validated instruments to assess disease activity and focuses on epidemiologic variables and biosamples (esophageal biopsies and blood specimens). An annual inclusion of 70 new patients with eosinophilic esophagitis (EoE) or proton pump inhibitor-responsive esophageal eosinophilia (PPI-REE) is intended. We herein describe the SEECS cohort profile.
The SEECS includes adult patients (age ≥18 years) with EoE or PPI-REE diagnosed according to published criteria. After inclusion, the patients are typically seen once a year for a clinical and endoscopic/histologic follow-up examination. Data are captured using validated questionnaires. Biosamples from patients with gastroesophageal reflux disease (GERD) and controls with a healthy esophagus are collected as well.
From January 2016 to July 2017, a total of 111 patients with EoE and 10 patients with PPI-REE were recruited. In addition, esophageal biopsies and blood samples from 11 patients with GERD and 20 controls with a healthy esophagus were collected. The mean age of the patients with EoE and those with PPI-REE was 39.6 ± 12.9 and 44.6 ± 15.6 years, respectively. A male predominance was found among both the patients with EoE (77.5%) and those with PPI-REE (70%). Concomitant allergic disorders were found in 79.3% of the patients with EoE and 90% of the patients with PPI-REE. At inclusion, the EoE patients were treated with the following therapeutic regimens: no therapy (0.9%), PPI (36%), swallowed topical corticosteroids (82.9%), elimination diets (15.3%), and esophageal dilation (19.8%).
The SEECS is the first national cohort study of patients with EoE or PPI-REE. The SEECS will provide up-to-date epidemiologic data and foster translational research projects.
前瞻性观察性瑞士嗜酸性食管炎队列研究(SEECS)于2015年启动,旨在实现以下目标:(1)提供最新的流行病学数据;(2)评估医疗护理的适宜性;(3)评估心理社会影响;(4)推动转化研究项目。数据采集依赖经过验证的工具来评估疾病活动情况,并聚焦于流行病学变量和生物样本(食管活检组织和血液样本)。计划每年纳入70例新的嗜酸性食管炎(EoE)或质子泵抑制剂反应性食管嗜酸性粒细胞增多症(PPI-REE)患者。我们在此描述SEECS队列概况。
SEECS纳入根据已发表标准诊断为EoE或PPI-REE的成年患者(年龄≥18岁)。纳入后,患者通常每年接受一次临床及内镜/组织学随访检查。使用经过验证的问卷采集数据。还收集了胃食管反流病(GERD)患者及食管健康对照者的生物样本。
2016年1月至2017年7月,共招募了111例EoE患者和10例PPI-REE患者。此外,收集了来自11例GERD患者和20例食管健康对照者的食管活检组织和血液样本。EoE患者和PPI-REE患者的平均年龄分别为39.6±12.9岁和44.6±15.6岁。EoE患者(77.5%)和PPI-REE患者(70%)中男性均占主导。79.3%的EoE患者和90%的PPI-REE患者伴有过敏性疾病。纳入时,EoE患者接受以下治疗方案:未治疗(0.9%)、质子泵抑制剂(PPI,36%)、吞咽局部糖皮质激素(82.9%)、排除饮食(15.3%)及食管扩张(19.8%)。
SEECS是首个关于EoE或PPI-REE患者的全国性队列研究。SEECS将提供最新的流行病学数据并推动转化研究项目。